Charting Only., page-1975

The reality is our market cap is only US$ 140 million.
Our competitors are getting bought out for between US$ 5 Billion and US$ 21 Billion, whilst they are still in clinical trials, before they have even completed Ph 2
Not just one offs... Astra Zeneca, Gilead, Merck, BMS, Takeda, do your homework , these deals have generally been for single product pipeline that are not as cutting edge technology as the Imugene BCell platform for the CF33 OV.

whether or not some people are unemployed or some small businesses have been forced to shut is immaterial to the outcome here, the fact is Big Pharma have not shut down and will not shut down, and when they see compelling data they will step up.

Do do your homework on what drugs we have the ability to either improve on in combination with, or replace completely. We’ve just seen Gilead pay US$21 billion for a product that extends PFS from 1.7months to 5.6 months. We know in the HerVax Ph1b trial median PFS was 355 days from 3 patients.
So what do you think the outcome will be when we see that kind of result on 20 or more patients, when the SOC is less than 100 days??

Then factor in some value for the PD1 and CF33.

Downside looks very limited , upside looks at least 10, 20 X if you ignore all the unlrelated noise and let this unfold.